Genmab A/S Files Form 6-K for March 2024
Ticker: GNMSF · Form: 6-K · Filed: Mar 15, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Mar 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, registration-statement
Related Tickers: GMAB
TL;DR
Genmab filed a 6-K on 3/15/24, incorporating into its S-8 filings.
AI Summary
Genmab A/S filed a Form 6-K on March 15, 2024, to report information for the month of March 2024. This report is incorporated by reference into several of Genmab's S-8 registration statements, including File No. 333-277273.
Why It Matters
This filing serves as an update and is incorporated into existing registration statements, potentially affecting investors tracking the company's ongoing disclosures.
Risk Assessment
Risk Level: low — This is a routine filing that incorporates previous information into registration statements, not announcing new material events.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 0001558370-24-003311 (filing_id) — Accession Number
- 20240315 (date) — Filing Date
- 333-232693 (registration_statement_id) — Incorporated S-8 File Number
- 333-253519 (registration_statement_id) — Incorporated S-8 File Number
- 333-262970 (registration_statement_id) — Incorporated S-8 File Number
- 333-277273 (registration_statement_id) — Incorporated S-8 File Number
FAQ
What type of report is Genmab A/S filing?
Genmab A/S is filing a Form 6-K report.
What is the filing date of this Form 6-K?
The filing date is March 15, 2024.
What is the purpose of this Form 6-K filing?
This report is for the month of March 2024 and is incorporated by reference into Genmab A/S's registration statements.
Which registration statements does this 6-K filing get incorporated into?
This filing is incorporated into Genmab A/S's registration statements on Form S-8, specifically File Numbers 333-232693, 333-253519, 333-262970, and 333-277273.
What is Genmab A/S's principal executive office address?
The principal executive offices are located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Stats: 222 words · 1 min read · ~1 pages · Grade level 14.5 · Accepted 2024-03-15 09:46:15
Filing Documents
- tmb-20240315x6k.htm (6-K) — 18KB
- tmb-20240315xex99d1.htm (EX-99.1) — 28KB
- tmb-20240315xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-003311.txt ( ) — 54KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: March 15, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated March 15, 2024: Genmab Announces Initiation of Share Buy-Back Program